Clinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid Tumors

Summary

Clinical study of oral PI3K/mTOR inhibitor P7170 in patients with advanced refractory solid tumors. The primary objective is to determine the maximum tolerated dose and dose limiting toxicity of oral PI3K/mTOR inhibitor P7170 in patients with advanced refractory solid tumors

Timeline

Start

2012-09

Primary completion

2015-11

Completion

2016-03

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision not related to patient safety”

Drugs

Indications